We provide GLP-1 peptide, please refer to the following website for detailed specifications and product information.
Product: https://www.bloomtechz.com/synthetic-chemical/peptide/glp-1-peptide-cas-87805-34-3.html
1.General Specification(in stock)
(1)API(Pure powder)
(2)Injection
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Code: BM-2-4-113
English name: GLP-1 CAS 87805-34-3
Molecular formula: C186H275N51O59
EINECS No.: 201-258-5
Hs code: 3504009000
Main market: USA, Australia, Brazil, Japan, UK, New Zealand , Canada etc.
Lilly oral small molecule GLP-1 receptor agonist approved for market launch
On April 1, 2026, Eli Lilly announced that its oral small molecule GLP-1 receptor agonist Orforge lipon has been approved by the US FDA for the treatment of adult obesity or overweight. It is worth mentioning that this drug is the world's first approved oral small molecule non peptide GLP-1 receptor agonist (GLP-1 RA), marking a milestone in the field of small molecule GLP-1 RA.
Orforalipron is a small molecule (non peptide) GLP-1 RA that is orally administered once a day, originally discovered by domestic and foreign pharmaceutical companies. In 2018, Eli Lilly obtained the development authorization for the drug and advanced subsequent clinical research. Orforge lipon has a significant advantage of convenient administration, which can be taken at any time of the day without being restricted by diet or water. This approval is mainly based on the positive results of the ATTAIN series in vitro clinical trials.
This research project includes two global registered studies, involving more than 4500 obese or overweight patients in total. The ATIIN-1 study (NCTO5869903) is a 72 week randomized, dual tone, placebo-controlled dish study to evaluate the efficacy and safety of Orforglipron (6 mg, 12 mg, 36 mg) single drug treatment in obese adults or overweight adults with at least one complication (such as hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease) but no diabetes.
Domestic FIC nuclear drug approved for market launch
On April 2, 2026, the official website of the National Medical Products Administration (NMPA) showed that Ruidiao's Class 1 radioactive innovative drug technetium [99mTc Peseret Peptide Injection and the injection technetium used to prepare the drug! The 99mIcI pembrolizumab peptide kit has been approved for marketing through the priority review and approval process, and is used as an auxiliary examination for regional lymph node metastasis in suspected lung cancer patients. This drug is a Class 1 nuclear medicine radiological diagnostic new drug launched by domestic pharmaceutical companies on FI targets, and it is also the world's first broad-spectrum tumor imaging agent used for SPECT imaging.
[99mTc] Peseret peptide, formerly known as technetium [99mTc] hydrazine nicotinamide polyethylene glycol bicyclic RGD peptide (99mTC-3PRGD2), is a radiopharmaceutical developed independently by Redio, a subsidiary of Beijing Jilentai Pharmaceutical Co., Ltd. It targets integrin avB3 positive tumors and uses single photon emission and X-ray computed tomography (SPECT/CT) imaging system for imaging, mainly used for chest tumors, including diagnosis, differentiation, and evaluation of primary lung tumors and metastases.
In November 2023, Baiyang Pharmaceutical released an announcement that after the approval of the State Drug Administration for the launch of Radio series of radioactive drugs, Baiyang Pharmaceutical or its designated party will obtain the commercial rights and interests of the products and be responsible for the exclusive promotion and sales of the cooperative products in the Chinese Mainland market.
At the annual meeting of the American Society of Clinical Oncology (ASCO) in 2025, Redio announced the results of the phase III clinical trial of [99mTc] pembrolizumab peptide, clarifying the advantages of targeted integrin av β 3 imaging technology in the diagnosis of lymph node metastasis in lung cancer.
The siRNA new drug ABA001, jointly developed by Anlong Biotech and Sunshine Novo, has been officially approved for clinical use
On April 3, 2026, Anlong Biotechnology and Sunshine Novo announced today that the innovative SRNA drug ABA001 (acceptance number: CXHL2600091) for the treatment of hypertension, jointly developed by the two parties, has been officially approved for clinical trials by the National Medical Products Administration (NMPA)
ABA001 is a new type of antihypertensive drug with completely independent intellectual property rights, developed and promoted through deep cooperation between Anlong Biotechnology and Sunshine Novo. This product is based on innovative molecular design and sustained-release technology pathways, aiming to achieve longer dosing intervals and smoother blood drug concentrations. It is expected to break through the limitations of daily use of existing hypertension drugs and significantly improve patient medication compliance. Hypertension is one of the most common chronic diseases in China, and long-term poor control will significantly increase the risk of cardiovascular and cerebrovascular events.
Most commonly used antihypertensive drugs in clinical practice need to be taken once or multiple times a day, and patients are prone to problems such as missed or forgotten doses, leading to blood pressure fluctuations. If ABA001 can be successfully launched, it is expected to help patients achieve simpler and more stable blood pressure management by extending the dosing cycle, effectively improving their quality of life and long-term prognosis.